Kalaris Therapeutics (NASDAQ:KLRS) Announces Earnings Results

Kalaris Therapeutics (NASDAQ:KLRS) posted its quarterly earnings results on Tuesday. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.12, FiscalAI reports.

Kalaris Therapeutics Price Performance

Shares of NASDAQ KLRS opened at $7.53 on Thursday. The stock has a market capitalization of $140.81 million, a price-to-earnings ratio of -1.79 and a beta of -0.13. The firm’s 50 day simple moving average is $9.44 and its 200-day simple moving average is $7.28. Kalaris Therapeutics has a 12 month low of $2.14 and a 12 month high of $12.90.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Chardan Capital initiated coverage on shares of Kalaris Therapeutics in a report on Tuesday, December 23rd. They set a “buy” rating and a $19.00 price objective on the stock. Wall Street Zen upgraded Kalaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kalaris Therapeutics in a research report on Monday, December 29th. Finally, Citigroup reiterated an “outperform” rating on shares of Kalaris Therapeutics in a research note on Thursday, December 18th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $14.00.

Institutional Trading of Kalaris Therapeutics

A number of hedge funds have recently added to or reduced their stakes in KLRS. Nano Cap New Millennium Growth Fund L P purchased a new position in Kalaris Therapeutics in the fourth quarter valued at $34,000. Barclays PLC purchased a new stake in shares of Kalaris Therapeutics during the 4th quarter worth about $51,000. Johnson Financial Group Inc. acquired a new stake in shares of Kalaris Therapeutics during the 3rd quarter valued at about $58,000. XTX Topco Ltd purchased a new position in shares of Kalaris Therapeutics in the 2nd quarter valued at about $65,000. Finally, Keel Point LLC purchased a new position in shares of Kalaris Therapeutics in the 4th quarter valued at about $86,000. 66.05% of the stock is owned by hedge funds and other institutional investors.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.